do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline guidance SGLT-2 inhibitors, GLP The mechanism of action of

We prioritize patient safety and personalized care

Weight Loss with GLP-1 Medicines Does Not Result in a Disproportionate Loss of Muscle Mass or Function in Obese Mice and Humans. Cell Reports

A Pipeline Teeming with Innovation Beyond todays leading therapies like Mounjaro, Zepbound, Ozempic, and Wegovy, a robust pipeline of next-generation obesity drugs is advancing through clinical development, with several candidates already filed for regulatory approval

So we think there will be still some struggle for a couple of years

On-site solvent reprocessing: Some manufacturers are going beyond localized rinse reuse by installing on-site distillation or purification systems that enable full-scale, closed-loop solvent recycling